Our in vivo studies are delivered through a dedicated specialist company that operates as an integral part of our discovery ecosystem.
By structuring in vivo pharmacology within a focused organisation, we ensure deep scientific expertise, state-of-the-art infrastructure, and high-quality, reproducible data. This model allows each team to concentrate on its core strengths while maintaining full alignment across all stages of drug discovery.
For our clients, this means:
- Seamless project execution from early discovery through in vivo validation
- A single point of contact and unified scientific oversight
- Flexible and scalable study design tailored to project needs
- Consistent quality and regulatory standards
Despite the organisational structure, projects are managed as a fully integrated programme, ensuring continuity, transparency, and efficiency throughout.
Pharmacokinetics
Pharmacokinetics (PK) reveals the fate of substances in the body over time. The compounds can be administered in multiple ways, among which peroral (PO) and intravenous (IV) are the most popular ones. Cassette dosing in PK studies enables efficient, simultaneous evaluation of multiple compounds, offering early insight into in vivo interactions and supporting faster decision-making.
All PK studies can be customized upon request.
In vivo models
In vivo models play a pivotal role in the drug discovery process. Evaluation of the lead compounds in living organisms for safety and efficacy remains one of the main requirements before clinical studies in humans. In our studies, we strive to minimize the use of vertebrate species and, whenever possible, develop in vitro models for the lead compound evaluation. However, some complex diseases, e.g., diabetes, require the enrolment of experimental animals.
Our bioanalytical laboratory holds national regulatory certification to provide bioanalytical support for clinical bioavailability and bioequivalence studies.
We work closely with our customers to develop ADME/PK programs tailored to their project needs, ensuring a flexible approach that aligns with requirements and specifications. This may include high-throughput ADME analysis and an Express ADME panel to accommodate large sets and strict deadlines.